SCHEMBL20794232

SCHEMBL20794232

Cc1cc([C@H]2OC(=O)N(C(C)C)[C@H]2C)ccn1

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 7/20 0.38
FADS1 O60427 5/20 0.33
GRM2 Q14416 1/20 0.32
IDO1 P14902 1/20 0.32
UHRF1 Q96T88 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20794231 0.87 IDH1 (0.36) IDH1FADS1GRM2
SCHEMBL20780274 0.85 IDH1 (0.38) IDH1FADS1
SCHEMBL20780278 0.82 FADS1 (0.40) IDH1FADS1
SCHEMBL22222443 0.82 IDH1 (0.36) IDH1FADS1GRM2IDO1UHRF1
SCHEMBL20780445 0.81 IDH1 (0.39) IDH1FADS1GRM2
SCHEMBL20794440 0.79 HSD11B1 (0.41) IDH1FADS1
SCHEMBL23717394 0.78 PTGDR2 (0.34) IDH1FADS1GRM2
SCHEMBL18826417 0.76 IDH1 (0.44) IDH1FADS1
SCHEMBL18826430 0.76 IDH1 (0.44) IDH1FADS1
SCHEMBL13547531 0.76 KDM4E (0.44) FADS1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210290623-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2021-09-23 US disclosed
US-20200222406-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) 2020-07-16 US disclosed
US-20190070178-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2019-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200222406-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS HMGCR, PCSK9, FABP3 IDH1 4358/4885FADS1 318/4885GRM2 2768/4885
US-20190070178-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS HMGCR, PCSK9, FABP3 IDH1 4358/4885FADS1 318/4885GRM2 2768/4885
US-20210290623-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS HMGCR, PCSK9, FABP3 IDH1 4358/4885FADS1 318/4885GRM2 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.